---
layout: page
title: Lab Experience
---

<style>
  details {
    border: 1px solid #ddd;
    border-radius: 6px;
    padding: 1rem 1.5rem;
    margin-bottom: 1rem;
    background: #fafafa;
    transition: background 0.3s ease;
  }
  details[open] {
    background: #f0f8ff;
  }
  summary {
    font-size: 1.3rem;
    font-weight: 600;
    cursor: pointer;
    list-style: none;
  }
  summary::-webkit-details-marker {
    display: none;
  }
  summary:before {
    content: "â–¶";
    display: inline-block;
    margin-right: 10px;
    transition: transform 0.3s ease;
  }
  details[open] summary:before {
    transform: rotate(90deg);
  }
  ul {
    padding-left: 1.2rem;
    margin-top: 0.5rem;
  }
  ul li {
    margin-bottom: 0.5rem;
  }
  a {
    color: #007ACC;
    text-decoration: none;
    border-bottom: 1px solid transparent;
    transition: border-bottom 0.2s ease;
  }
  a:hover {
    border-bottom: 1px solid #007ACC;
  }
</style>

**Whilst I am looking to transition into a bioinformatic role, I also have extensive wet lab experience and understanding of cutting-edge platforms.**

<details open>
  <summary><strong>ðŸ§¬ Spatial Profiling</strong></summary>
  <ul>
    <li>Experienced with multiplexed spatial imaging platforms including <strong>Cell DIVE</strong> and <strong>PhenoCycler Fusion</strong>.</li>
    <li>Have run projects dealing with high volumes of slides (50+ Cell DIVE) or biomarkers (60-plex Phenocycler).</li>
  </ul>
</details>

<details>
  <summary><strong>ðŸ’Š Drug Discovery and Screening</strong></summary>
  <ul>
    <li>Delivered lead compound currently under evaluation with a commercial partner - <a href="https://www.qmul.ac.uk/blizard/about/news/items/queen-mary-research-team-heads-discovery-of-a-new-method-to-stop-the-growth-of-cancer-cells.html" target="_blank">Press Release</a></li>
    <li>Numerous rounds of lead optimisation as part of a multidisciplinary cross-University team (Dundee Drug Discovery Unit) to explore series structural activity relationships.</li>
    <li>Conducted high-throughput compound screening in 384-well format across multiple cancer cell lines.</li>
    <li>Operated IN Cell Analyzer 2200/6000 (including confocal mode) for high-content automated imaging.</li>
  </ul>
</details>

<details>
  <summary><strong>ðŸ¤– Automation and Robotic Integration</strong></summary>
  <ul>
    <li>Robotic automation experience using platforms such as PAA and CyBio FeliX for high-throughput liquid handling and assay miniaturisation.</li>
    <li>Operated BOND Rx automated slide stainer for multiplexed staining protocols.</li>
    <li>BAB robotics for Cell DIVE workflow automation.</li>
  </ul>
</details>

<details>
  <summary><strong>ðŸ§« Cell Biology & Senescence Models</strong></summary>
  <ul>
    <li>Long-term culture of adult primary cells (&gt;200 days) and use of 3D spheroid models.</li>
    <li>Experienced with multiple senescence models: replicative (RS), oncogene-induced (OIS), therapy-induced (TIS), and paracrine senescence.</li>
    <li>Maintained a range of cancer cell lines (e.g. MB-468, MB-231, BT549, HCC1937, HeLa) in antibiotic-free conditions.</li>
  </ul>
</details>

<details>
  <summary><strong>ðŸ“¦ Extracellular Vesicle (EV) Isolation & Characterisation</strong></summary>
  <ul>
    <li>EV isolation via ultracentrifugation and size-exclusion chromatography.</li>
    <li>Characterisation using nanoparticle tracking analysis (NTA) and nano-flow cytometry.</li>
  </ul>
</details>

<details>
  <summary><strong>ðŸ§¬ Molecular Biology Techniques</strong></summary>
  <ul>
    <li>Proficient in standard laboratory techniques including Western blotting, ELISA, PCR, and qPCR.</li>
  </ul>
</details>
